{"id":309570,"date":"2026-02-16T00:00:00","date_gmt":"2026-02-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2024-biopharma-chronic-obstructive-pulmonary-disease-landscape-forecast-disease-landscape-2\/"},"modified":"2026-05-03T11:09:55","modified_gmt":"2026-05-03T11:09:55","slug":"dlsfim0003-2026-biopharma-chronic-obstructive-pulmonary-disease-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0003-2026-biopharma-chronic-obstructive-pulmonary-disease-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Chronic Obstructive Pulmonary Disease &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>The chronic obstructive pulmonary disease (<abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>) market continues to gradually shift away from <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s toward <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s and <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s, but current and emerging generics are expected to have an impact on this trend. Some generic <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s and <abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>s have already launched in the United States and Europe, and more will reach the market in the coming years, together with generics for triple therapies. Although physicians will welcome additional treatment options for this chronic disease as a result of the development and launch of novel drug classes, including biologics (e.g.,<abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-4 \/ <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-13 inhibitors, <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-5 inhibitors, <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-33 inhibitors, and <abbr data-abbreviation-entity=\"5510\" title=\"thymic stromal lymphopoietin\">TSLP<\/abbr> inhibitors) and novel nebulized therapies (e.g., <abbr data-abbreviation-entity=\"5503\" title=\"phosphodiesterase\">PDE<\/abbr>3\/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue and\/or halt disease progression.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What impact will <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s have on the market share of other inhaled therapies (e.g., <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4874\" title=\"long-acting muscarinic antagonist\">LAMA<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s, <abbr data-abbreviation-entity=\"4873\" title=\"long-acting beta2 agonist\">LABA<\/abbr>\/<abbr data-abbreviation-entity=\"4859\" title=\"inhaled corticosteroid\">ICS<\/abbr> <abbr data-abbreviation-entity=\"4818\" title=\"fixed-dose combination\">FDC<\/abbr>s)<\/li>\n<li>What is the use and overall acceptance of newly launched biologics dupilumab and mepolizumab?<\/li>\n<li>What are key opinion leaders\u2019 insights on current treatment options (e.g., GSK\u2019s Trelegy, Advair, Breo, Nucala; GSK \/ Innoviva\u2019s Anoro; BI\u2019s Spiriva, Stiolto \/ Spiolto; AstraZeneca\u2019s Breztri\u00a0\/ Trixeo, Symbicort; Sanofi \/ Regeneron dupilumab)? What factors drive physicians\u2019 treatment decisions?<\/li>\n<li>Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of <abbr data-abbreviation-entity=\"4864\" title=\"interleukin\">IL<\/abbr>-33 and <abbr data-abbreviation-entity=\"5510\" title=\"thymic stromal lymphopoietin\">TSLP<\/abbr> inhibitors be accepted for <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>? How will the launch of these and other biologics influence the <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> market?<\/li>\n<li>How will the market evolve over the 10-year forecast period?<\/li>\n<li>What are the unmet needs for <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States, EU5, Japan<\/p>\n<p><strong>Primary research:<\/strong> Country-specific interviews with thought-leading pulmonologists; supported by survey data collected for this and other Clarivate research<\/p>\n<p><strong>Epidemiology:<\/strong> Number of drug-treated <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> patients by country, segmented by severity (mild to moderate, severe to very severe)<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"4770\" title=\"chronic obstructive pulmonary disease\">COPD<\/abbr> therapies through 2034, segmented by brands \/ generics and epidemiological subpopulations (mild to moderate, severe to very severe)<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product <\/strong><strong>description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-309570","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-obstructive-pulmonary-disease","biopharma-therapy-areas-respiratory","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/309570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":9,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/309570\/revisions"}],"predecessor-version":[{"id":575200,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/309570\/revisions\/575200"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=309570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}